Further, in stage IV and Ras wt CRC patients, high expression of both EGFR and EphA2 was indicative of poor prognosis and poor response to cetuximab, even in Ras wt expressing patients, with only EphA2low patients showing significant responses (Table 1) [62]. The gene discussed is EPHA2; the disease is colorectal carcinoma.